SERO-388 was never meant for human trials. It was synthesized in 2038 (or 2041, depending on which leaked dataset you trust) as a selective inverse agonist of the 5-HT₂A receptor—but with a peculiar secondary affinity for the default mode network’s glutamatergic pacemaker cells. In lay terms, it doesn’t just alter consciousness. It performs a precise, reversible surgical ablation of the narrative self.
“If we give this to everyone, who will be left to mourn the loss?” sero-388
In today's [industry/field], [explain why sero-388 is significant]. Its innovative approach to [specific challenge or area] could [potential impact or change]. SERO-388 was never meant for human trials
IntelliCheck